Minakem-flap
Minakem-flap

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2021

            Details:

            The primary endpoint, vaccine (AZD1222) efficacy at preventing symptomatic COVID-19 was 76% (confidence interval (CI): 68% to 82%) occurring 15 days or more after receiving two doses given four weeks apart.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2021

            Details:

            The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 15, 2021

            Details:

            The independent monitors are analyzing data from the 32,000-person U.S. study to determine whether the AstraZeneca Plc’s U.S. COVID-19 vaccine (AZD1222) is safe and effective.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cabotegravir,Rilpivirine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Cabenuva

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 06, 2021

            Details:

            ATLAS-2M met its primary endpoint at Week 48, demonstrating that the efficacy of long-acting cabotegravir and rilpivirine dosed every 2-months (every eight weeks) was non-inferior to monthly dosing (every four weeks).